COVID-19 Testing May Be Here to Stay, Suggests Study of 'Breakthrough' Cases
|
By LabMedica International staff writers Posted on 26 Apr 2021 |

Image: Teresa Rozza of Rockefeller’s Clinical Genomics Lab runs COVID saliva tests for the whole university community (Photo courtesy of Matthew Septimus)
A study of rare cases in which people who have been fully vaccinated against COVID and are immune to the virus can nevertheless develop the disease suggests that COVID testing may be here to stay.
New findings from The Rockefeller University (New York, NY, USA) suggest that these so-called breakthrough cases may be driven by rapid evolution of the virus, and that ongoing testing of immunized individuals will be important to help mitigate future outbreaks.
The research reports results from ongoing monitoring within the Rockefeller University community where two fully vaccinated individuals tested positive for the coronavirus. Both had received two doses of either the Moderna or the Pfizer vaccine, with the second dose occurring more than two weeks before the positive test. One person was initially asymptomatic and then developed typical COVID-19 symptoms; the other developed symptoms prior to testing. Both individuals recovered at home, an outcome consistent with evidence suggesting vaccination is effective in preventing severe disease.
Genome sequencing revealed multiple mutations in both viral samples, including the E484K variant in one individual, first identified in South Africa and Brazil, and the S477N variant in the other individual, which has been spreading in New York since November. The researchers were able to discern a quantifiable amount of virus in saliva samples from routine testing ongoing at Rockefeller, and sequence the viral RNA using a new coronavirus testing method. The observations suggest what is likely a small but ongoing risk among vaccinated individuals and the possibility that they may continue to spread the virus.
“These patients got vaccinated, had great immune responses, and nonetheless broke through with a clinical infection,” said Robert B. Darnell, The Robert and Harriet Heilbrunn Professor, who led the research. “The idea that we could be entirely done with testing in the post-vaccine world is probably not a good one right now; for example, even fully vaccinated people who develop respiratory symptoms should consider getting tested for COVID-19. Conversely, exposure to individuals with known infection, even if fully vaccinated, should be taken seriously and again individuals should consider getting tested.”
Related Links:
The Rockefeller University
New findings from The Rockefeller University (New York, NY, USA) suggest that these so-called breakthrough cases may be driven by rapid evolution of the virus, and that ongoing testing of immunized individuals will be important to help mitigate future outbreaks.
The research reports results from ongoing monitoring within the Rockefeller University community where two fully vaccinated individuals tested positive for the coronavirus. Both had received two doses of either the Moderna or the Pfizer vaccine, with the second dose occurring more than two weeks before the positive test. One person was initially asymptomatic and then developed typical COVID-19 symptoms; the other developed symptoms prior to testing. Both individuals recovered at home, an outcome consistent with evidence suggesting vaccination is effective in preventing severe disease.
Genome sequencing revealed multiple mutations in both viral samples, including the E484K variant in one individual, first identified in South Africa and Brazil, and the S477N variant in the other individual, which has been spreading in New York since November. The researchers were able to discern a quantifiable amount of virus in saliva samples from routine testing ongoing at Rockefeller, and sequence the viral RNA using a new coronavirus testing method. The observations suggest what is likely a small but ongoing risk among vaccinated individuals and the possibility that they may continue to spread the virus.
“These patients got vaccinated, had great immune responses, and nonetheless broke through with a clinical infection,” said Robert B. Darnell, The Robert and Harriet Heilbrunn Professor, who led the research. “The idea that we could be entirely done with testing in the post-vaccine world is probably not a good one right now; for example, even fully vaccinated people who develop respiratory symptoms should consider getting tested for COVID-19. Conversely, exposure to individuals with known infection, even if fully vaccinated, should be taken seriously and again individuals should consider getting tested.”
Related Links:
The Rockefeller University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read moreMolecular Diagnostics
view channel
Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
Cervical cancer remains highly preventable, yet screening access is limited in many low- and middle-income settings. Gold-standard tests for high-risk human papillomavirus (HPV) detect viral DNA or messenger... Read more
Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
Most prostate cancers depend on androgen signaling, making hormone suppression or blockade a central treatment strategy. Although many patients respond initially, tumors often adapt and eventually progress,... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more









